ArticleTrends in analytical chemistry : TRAC2025
Multifunctional Nanobody Fusion Proteins in Immunoassays: Diverse Strategies for Enhanced Analytical Performance.
Article in Trends in analytical chemistry : TRAC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Article
- Molecular Characterization of Representative CPV-2c Isolates and Establishment of VP2-Targeted Nanobody-Based Immunodetection Tools.Animals : an open access journal from MDPI · 2026Article
- Assessing structural prediction accuracy for nanobody-small molecule complexes.Protein engineering, design & selection : PEDS · 2026Article
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nanobodies, derived from camelid heavy-chain antibodies, offer exceptional specificity, stability, and solubility, enabling rapid and sensitive immunoassays. Their small size makes them ideal scaffolds for genetic fusion with reporter proteins, functional peptides, and signal amplification modules. In contrast to conventional antibodies, nanobodies can be precisely engineered at the gene level, allowing directional conjugation and efficient incorporation of signal-enhancing elements. This tunability simplifies assay design and reduces processing steps. Additionally, recombinant expression systems enable stable, scalable, and standardized production of nanobody-based immunoreagents, ensuring reproducibility in diagnostics. In this review, we summarize recent advances in the engineering and application of nanobody fusion proteins in immunoassays, with a particular focus on three main strategies: signal reporting, site-oriented strategies, and multivalency. We highlight how these approaches enhance sensitivity, shorten assay time, and enable multiplex detection. Finally, we discuss future perspectives and remaining challenges in the design and application of nanobody-based platforms for diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.